ELV Stock Analysis: Elevance Health | NYSE
Healthcare Plans | NYSE, USA | Market Cap: 83.805m USD | 12M Return: 17.5% | US0367521038 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 455M
EPS Trend: -74.3%
Qual. Beats: 2
Rev. Trend: 97.3%
Qual. Beats: 9
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Elevance Health, Inc. is a U.S.-based health benefits company headquartered in Indianapolis, Indiana, that operates through four reportable segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. The company provides health plans and related services to individual, employer group, BlueCard, Medicare, Medicaid, and Federal Employees Program (FEP) members, while also offering specialty and supplemental products such as dental, vision, and stop loss insurance. Its pharmacy services business, branded CarelonRx, includes home delivery, specialty pharmacies, claims adjudication, formulary management, rebate administration, and infusion services, and its Carelon Services segment delivers care management, behavioral health, palliative care, virtual care, payment integrity, clinical analytics, and post-acute and home-based care support. The company markets its offerings under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands, and was renamed from Anthem, Inc. to Elevance Health, Inc. in June 2022.
As one of the major publicly traded U.S. managed care organizations in the GICS Managed Health Care sub-industry, Elevance Health operates an integrated payer-and-services model in which the same company underwrites insurance risk (its Blue-licensed health plans), administers pharmacy benefits, and sells care-delivery-adjacent services to other insurers and providers. This vertical integration-combining a health insurer with a captive PBM and a portfolio of clinical and administrative services-has become a common structural approach among large U.S. health plans seeking to capture additional margin across the healthcare value chain.
- Medicare Advantage medical costs pressure benefit ratios
- CarelonRx pharmacy segment drives margin expansion
- Medicaid redeterminations pressure state contract margins
| Net Income: 4.96b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 0.60 > 1.0 |
| NWC/Revenue: 17.11% < 20% (prev 1.98%; Δ 15.12% < -1%) |
| CFO/TA 0.06 > 3% & CFO 7.46b > Net Income 4.96b |
| Net Debt (-6.47b) to EBITDA (8.01b): -0.81 < 3 |
| Current Ratio: 2.05 > 1.5 & < 3 |
| Outstanding Shares: last quarter (217.9m) vs 12m ago -3.50% < -2% |
| Gross Margin: 38.95% > 18% (prev 26.84%; Δ 12.12% > 0.5%) |
| Asset Turnover: 161.9% > 50% (prev 155.2%; Δ 6.74% > 0%) |
| Interest Coverage Ratio: 6.19 > 6 (EBIT TTM 6.99b / Interest Expense TTM 1.13b) |
| A: 0.27 (Total Current Assets 67.2b - Total Current Liabilities 32.8b) / Total Assets 126b |
| B: 0.29 (Retained Earnings 36.7b / Total Assets 126b) |
| C: 0.06 (EBIT TTM 6.99b / Avg Total Assets 124b) |
| D: 0.55 (Book Value of Equity 44.9b / Total Liabilities 81.4b) |
| Altman-Z'' = 3.69 = AA |
| DSRI: 1.38 (Receivables 23.4b/15.9b, Revenue 201b/189b) |
| GMI: 0.69 (GM 26.84% / 38.95%) |
| AQI: 0.57 (AQ_t 0.43 / AQ_t-1 0.76) |
| SGI: 1.06 (Revenue 201b / 189b) |
| TATA: -0.02 (NI 4.96b - CFO 7.46b) / TA 126b) |
| Beneish M = -3.21 (Cap -4..+1) = AA |
As of October 11, 2026, the stock is trading at USD 412.70 with a total of 2,076,761 shares traded. Over the past week, the price has changed by +6.80%, over one month by +4.43%, over three months by -1.40% and over the past year by +17.53%.
Current recommended Stop Loss: 396.40 (which is 3.9% or 1.7 ATR below the current price).
Elevance Health has received a consensus analysts rating of 4.18. Therefore, it is recommended to buy ELV.
- StrongBuy: 12
- Buy: 2
- Hold: 8
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 451.4 | 9.4% |
P/E Trailing = 16.8894
P/E Forward = 13.6799
P/S = 0.4167
P/B = 1.9258
P/EG = 1.3035
Revenue TTM = 201b USD
EBIT TTM = 6.99b USD
EBITDA TTM = 8.01b USD
Long Term Debt = 30.7b USD (from longTermDebt, last quarter)
Short Term Debt = 375.0m USD (from shortTermDebt, last quarter)
Debt = 31.0b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -6.47b USD (calculated: Debt 31.0b - CCE 37.5b)
Enterprise Value = 77.3b USD (83.8b + Debt 31.0b - CCE 37.5b)
Interest Coverage Ratio = 6.19 (Ebit TTM 6.99b / Interest Expense TTM 1.13b)
EV/FCF = 12.30x (Enterprise Value 77.3b / FCF TTM 6.29b)
FCF Yield = 8.13% (FCF TTM 6.29b / Enterprise Value 77.3b)
FCF Margin = 3.13% (FCF TTM 6.29b / Revenue TTM 201b)
Net Margin = 2.47% (Net Income TTM 4.96b / Revenue TTM 201b)
Gross Margin = 38.95% ((Revenue TTM 201b - Cost of Revenue TTM 123b) / Revenue TTM)
Gross Margin QoQ = 89.12% (prev 18.14%)
Tobins Q-Ratio = 0.61 (Enterprise Value 77.3b / Total Assets 126b)
Interest Expense / Debt = 3.64% (Interest Expense 1.13b / Debt 31.0b)
Taxrate = 15.61% (915.0m / 5.86b)
NOPAT = 5.90b (EBIT 6.99b * (1 - 15.61%))
Current Ratio = 2.05 (Total Current Assets 67.2b / Total Current Liabilities 32.8b)
Debt / Equity = 0.69 (Debt 31.0b / totalStockholderEquity, last quarter 44.9b)
Debt / EBITDA = -0.81 (Net Debt -6.47b / EBITDA 8.01b)
Debt / FCF = -1.03 (Net Debt -6.47b / FCF TTM 6.29b)
Total Stockholder Equity = 44.2b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.00% (Net Income 4.96b / Total Assets 126b)
RoE = 11.24% (Net Income TTM 4.96b / Total Stockholder Equity 44.2b)
RoCE = 9.34% (EBIT 6.99b / Capital Employed (Equity 44.2b + L.T.Debt 30.7b))
RoIC = 7.03% (NOPAT 5.90b / Invested Capital 84.0b)
WACC = 5.29% (E(83.8b)/V(115b) * Re(6.11%) + D(31.0b)/V(115b) * Rd(3.64%) * (1-Tc(0.16)))
Discount Rate = 6.11% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -98.49 | Cagr: -3.16%
[DCF] Terminal Value 77.97% ; FCFF base≈5.91b ; Y1≈6.77b ; Y5≈9.97b
[DCF] Fair Price = 721.5 (EV 150b - Net Debt -6.47b = Equity 156b / Shares 216.9m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -74.26 | EPS CAGR: -4.85% | SUE: 1.42 | # QB: 2
Revenue Correlation: 97.31 | Revenue CAGR: 7.79% | SUE: 2.95 | # QB: 9
EPS current Quarter (2026-09-30): EPS=4.66 | Chg30d=-0.08% | Revisions=-55% | Analysts=19
EPS current Year (2026-12-31): EPS=27.17 | Chg30d=+0.02% | Revisions=-25% | GrowthEPS=-10.3% | GrowthRev=-0.5%
EPS next Year (2027-12-31): EPS=29.54 | Chg30d=-0.22% | Revisions=+40% | GrowthEPS=+8.7% | GrowthRev=+1.9%
[Analyst] Revisions Ratio: -43% (up=5, down=15)